Dunhill Financial’s Charles River Laboratories CRL Stock Holding History

Dunhill Financial’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$466	Buy	2 +1	+100%	+$178	﹤0.01%	1147
2026 Q1	$312	Sell	1 -1	-50%	-$185	﹤0.01%	1181
2025 Q4	$493	Buy	2 +1	+100%	+$181	﹤0.01%	935
2025 Q3	$175	Hold	1	–	–	﹤0.01%	939
2025 Q2	$267	Sell	1 -12	-92%	-$1.6K	﹤0.01%	922
2025 Q1	$1.97K	Sell	13 -1	-7%	-$168	﹤0.01%	735
2024 Q4	$2.59K	Buy	14 +3	+27%	+$578	﹤0.01%	671
2024 Q3	$2.23K	Buy	11 +6	+120%	+$1.25K	﹤0.01%	697
2024 Q2	$1.11K	Buy	5 +1	+25%	+$227	﹤0.01%	675
2024 Q1	$1.16K	Hold	4	–	–	﹤0.01%	616
2023 Q4	$856	Buy	+4	New	+$787	﹤0.01%	630

Other funds holding CRL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Dunhill Financial's CRL Position: Q2 2026 in Review

Dunhill Financial increased its Charles River Laboratories (CRL) stake by 100% in Q2 2026, buying an estimated $178 and bringing the position to 2 shares worth $466. The position accounts for ﹤0.01% of the portfolio, ranked #1147.

Dunhill Financial first reported a position in CRL in Q4 2023 and has held it in 11 quarters since. The position peaked at $2.59K in Q4 2024. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

Dunhill Financial held 2 shares of Charles River Laboratories worth $466 as of Q2 2026.
Dunhill Financial bought 1 Charles River Laboratories share in Q2 2026, an estimated $178.
Charles River Laboratories made up ﹤0.01% of Dunhill Financial's portfolio in Q2 2026, its #1147 holding.
Dunhill Financial first reported a position in Charles River Laboratories in Q4 2023 and has held it in 11 quarters since.
Dunhill Financial's Charles River Laboratories position peaked at $2.59K in Q4 2024.
570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Dunhill Financial's 13F filing for Q2 2026, filed 7 Aug 2026.